

**DEBIOPHARM TO SHOWCASE RESEARCH RESULTS OF THEIR DDR INHIBITORS AT THE 2024 AACR CONFERENCE IN SAN DIEGO**

*Debiopharm announces poster presentations on data for their potentially best-in class compounds: Debio 0123, a brain-penetrant WEE1 inhibitor, and Debio 0432, a selective USP1 Inhibitor*

**Lausanne, Switzerland – April 4<sup>th</sup>, 2024** – Debiopharm ([www.debiopharm.com](http://www.debiopharm.com)), a privately-owned, Swiss-based biopharmaceutical company aiming to establish tomorrow’s standard-of-care to cure cancer and infectious diseases, today announced preclinical data releases for two of their compounds inhibiting the DNA-damage response (DDR) of cancer cells, including **Debio 0123** [selective WEE1 inhibitor] and **Debio 0432** [Selective USP1 Inhibitor] at the 2024 Annual American Association for Cancer Research (AACR) summit in San Diego, California.

*“Since 2017, Debiopharm has been growing its expertise in the DDR inhibitor field, firstly through its WEE1-inhibitor Debio 0123 and through the recently in-licensed asset, targeting USP1. These posters are proof of our commitment to stay at the forefront of DDR-inhibitor development and outsmart hard-to-treat cancers through synthetic lethality or other groundbreaking combinations.” - Angela Zubel, Chief Development Officer at Debiopharm*

<b>AACR 2024 Poster Presentations</b>	<b>Debiopharm compound</b>	<b>Title</b>	<b>Presenter</b>
Mon, April 8 <sup>th</sup> Poster display: 9:00-12:30pm Abstract #: CT064 Poster Section: 48 Poster Board #: 14	Debio 0123	<i>Impact of food and high gastric pH on the bioavailability of the WEE1 inhibitor Debio 0123 assessed in a Phase 1 dose escalation study</i>	Anne Bellon, Clinical Pharmacology Lead
Mon, April 8 <sup>th</sup> Poster display: 1:30-5:00pm Abstract #: 3370 Poster Section: 29 Poster Board #: 27	Debio 0123	<i>Anti-tumor activity of Debio 0123 in combination with sacituzumab govitecan in preclinical models of breast cancer</i>	Luke Piggott, Principal Scientist
Tue, April 9 <sup>th</sup> Poster display: 1:30-5:00pm Abstract #: 6507 Poster Section: 46 Poster Board #: 24	Debio 0123	<i>Simulation driven identification of combination for the WEE1 inhibitor Debio 0123 results in synergistic effect with cabozantinib validated in vivo</i>	Luke Piggott, Principal Scientist & Turbine AI
Wed, April 10 <sup>th</sup> Poster display: 9:00-12:30pm Abstract #: 7145 Poster Section: 23 Poster Board #: 7	Debio 0432	<i>Identification of Debio 0432 as a potent and selective USP1 inhibitor for cancer therapy</i>	Noemie Luong, Associate Principal Scientist

## **About DNA-Damage Repair (DDR)**

When cells have damaged DNA, they need to undergo a repair process called DDR to be able to survive. Cancer cells rely a lot on DDR as they divide and grow uncontrollably. Inhibition of DDR, particularly in combination with other anticancer agents, prevents cancer cells from repairing their DNA, which ultimately activates a self-destruction program in cancer cells. DDR inhibitors such as Debiopharm's WEE1 and USP1 inhibitors, are being tested in clinical and preclinical studies.

## **Debiopharm's commitment to cancer patients**

Debiopharm aims to develop innovative therapies that target high unmet medical needs in oncology and bacterial infections. Bridging the gap between disruptive discovery products and real-world patient reach, we identify high-potential compounds and technologies for in-licensing, clinically demonstrate their safety and efficacy, and then select large pharmaceutical commercialization partners to maximize patient access globally.

Visit us [www.debiopharm.com/drug-development/](http://www.debiopharm.com/drug-development/)

Follow us

<https://twitter.com/DebiopharmNews>

<https://www.linkedin.com/company/debiopharminternational/>